Literature DB >> 31662332

Management of the adult Fontan patient.

Fred H Rodriguez1,2, Wendy M Book3.   

Abstract

Adults with congenital heart disease who underwent the Fontan operation to palliate single ventricle heart defects-by direct connection of caval venous return to the pulmonary circulation-have improved survival due to advancements in surgical and interventional techniques. However, cardiac and non-cardiac comorbidities often coexist, complicating management, and contributing to premature morbidity and mortality. Cardiac issues include heart failure symptoms related to systolic and diastolic dysfunction, atrial and ventricular arrhythmias and systemic atrioventricular valve regurgitation. Structural issues may be related to obstruction of the Fontan pathway, or to branch pulmonary artery stenosis, both of which exacerbate symptoms. Non-cardiac complications in adults involve hepatic congestion, fibrosis and cirrhosis, hepatocellular carcinoma, chronic kidney disease, stroke, venous stasis, lymphatic issues and involvement of other organ systems. 'Fontan failure' refers to circulatory dysfunction, either cardiac, non-cardiac, or both, diagnosed after exclusion or treatment of reversible contributors such as structural issues and arrhythmias. Counselling about reproductive health, mental health, perioperative management and overall wellness are paramount for patients' well-being. Fontan patients are typically managed in highly specialised adult congenital heart centres, but may present to cardiologists or other practitioners with cardiac and non-cardiac emergencies or urgencies, sometimes after being out of care. In this review, we discuss the management of the adult Fontan patient, including surveillance, cardiac and non-cardiac complications, reproductive health, and advanced therapies. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Fontan physiology; complex congenital heart disease; congenital heart disease; heart failure with preserved ejection fraction; heart failure with reduced ejection fraction

Year:  2019        PMID: 31662332     DOI: 10.1136/heartjnl-2019-314937

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  3 in total

1.  Pharmacokinetics of treprostinil in children with functional single-ventricle pulmonary arterial hypertension: a randomized controlled trial.

Authors:  Xi Chen; Xiao-Man Cai; Ming-Jie Zhang; Jing-Han Xu; Hao Li; Zhuo-Ming Xu
Journal:  Ann Transl Med       Date:  2021-07

Review 2.  Long-term management of Fontan patients: The importance of a multidisciplinary approach.

Authors:  Diletta Martino; Caterina Rizzardi; Serena Vigezzi; Chiara Guariento; Giulia Sturniolo; Francesca Tesser; Giovanni di Salvo
Journal:  Front Pediatr       Date:  2022-08-25       Impact factor: 3.569

3.  Genetic Disruption of Guanylyl Cyclase/Natriuretic Peptide Receptor-A Triggers Differential Cardiac Fibrosis and Disorders in Male and Female Mutant Mice: Role of TGF-β1/SMAD Signaling Pathway.

Authors:  Umadevi Subramanian; Chandramohan Ramasamy; Samivel Ramachandran; Joshua M Oakes; Jason D Gardner; Kailash N Pandey
Journal:  Int J Mol Sci       Date:  2022-09-29       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.